| Literature DB >> 19251413 |
Diane B Hauze1, Murty V Chengalvala, Joshua E Cottom, Irene B Feingold, Lloyd Garrick, Daniel M Green, Christine Huselton, Wenling Kao, Kenneth Kees, Joseph T Lundquist, Charles W Mann, John F Mehlmann, John F Rogers, Linda Shanno, Jay Wrobel, Jeffrey C Pelletier.
Abstract
A previous report described the serum LH suppression pharmacology of the 2-phenyl-4-piperazinyl-benzimidazole N-ethyluracil GnRH receptor antagonist 1 following oral administration in rats. A series of small heterocycles were appended to the 2-(4-tert-butylphenyl)-4-piperazinyl-benzimidazole template in place of the N-ethyluracil. Two imidazole analogues, 32 and 41, were shown to possess substantial in vitro potency at the target receptor (hGnRH IC(50) = 7 and 18 nM, respectively) and aqueous solubility (55 and 100 microg/mL at pH 7.4, respectively). Both compounds had high oral bioavailability in rats and 32 was further examined in an orchidectomized rat model for serum LH suppression based on increased volume of distribution over 41. Serum LH levels trended lower in orchidectomized rats following oral administration of 32.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19251413 DOI: 10.1016/j.bmcl.2009.02.043
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823